Condition
Malignant Pleural Mesotherioma
Estimated Enrollment: 12
Age Group: 20 Years to 75 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 5249|H3E-JE-ME01
Study First Received: November 8, 2005
Last Updated: November 5, 2007
Estimated Primary Completion Date: null
Primary Outcome Measures:
To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate|Duration of response|Progression free survival|Median survival time|1 year survival rate|Pulmonary function|QOL|Safety|Plasma concentration
Sponsors and Collaborators:
Eli Lilly and Company
Website Link: https://ClinicalTrials.gov/show/NCT00251550
